Co-stimulatory molecules B7-1 and B7-2 as experimental therapeutic targets

Bibliography

• BLANDEN RV, LEFFORD MJ, MACKANESS GB: The hostresponse to Calmette-Guerin bacillus infection in mice. J. Exp. Med. (1969) 129(5):1079–1107.
   PubMedGoogle Scholar
• ROSENBERG AS, SINGER A: Cellular basis of skin allo-graft rejection: an in vivo model of immune-mediated tissue destruction. Ann. Rev. Immunol. (1992) 10:333–358.
   PubMed Web of Science ®Google Scholar
• GREENBERG PD: Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimina-tion of tumor cells. Adv. Immunol (1991) 49:281–355.
   PubMed Web of Science ®Google Scholar
• BLANDEN RV: Mechanisms of recovery from a general-ized viral infection: mousepox. 3. Regression infec-tious foci. J. Exp. Med. (1971) 133 (5) :1090–1104.
   PubMedGoogle Scholar
• BLANDEN RV: Mechanisms of recovery from a general-ized viral infection: mousepox. II. Passive transfer of recovery mechanisms with immune lymphoid cells. J. Exp. Med. (1971) 133(5):1074–1089.
   PubMedGoogle Scholar
• BLANDEN RV: Mechanisms of recovery from a general-ized viral infection: mousepox. I. The effects of anti-thymocyte serum. J. Exp. Med. (1970) 132 (5) :1035–1054.
   PubMedGoogle Scholar
• FINKELMAN FD, HOLMES J, KATONA IM, et al. Lym-phokine control of in vivo immunoglobulin isotype se-lection. Ann. Rev. Immunol. (1990) 8:303–333.
   PubMed Web of Science ®Google Scholar
• LINSLEY PS, CLARK EA, LEDBETTER JA: T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. Proc. Natl. Acad. ScL USA (1990) 87(13):5031–5035.
   PubMed Web of Science ®Google Scholar
• •Identification of B7–1 as a ligand for CD28.
   Google Scholar
• AZUMA M, ITO D, YAGITA H, et al.: B70 antigen is a sec-ond ligand for CTLA-4 and CD28. Nature (1993) 366(6450):76–79.
   PubMed Web of Science ®Google Scholar
• ••First cloning of B7–2 molecule.
   Google Scholar
• FREEMAN GJ, BORRIELLO F, HODES RJ et al.: Murine B7-2, an alternative CTLA4 counter-receptor that co-stimulates T cell proliferation and interleukin 2 pro-duction. J. Exp. Med. (1993) 178(6):2185–2192.
   PubMedGoogle Scholar
• WU Y, GUO Y, LIU Y: A major co-stimulatory molecule on antigen-presenting cells, CTLA4 ligand A, is distinct from B7. J. Exp. Med. (1993) 178(5):1789–1793.
   PubMedGoogle Scholar
• •Reveals the existence of B7–2.
   Google Scholar
• LAFFERTY KJ, CUNNINGHAM AJ: A new analysis of allo-geneic interactions. Aust. J. Exp. Biol. Med. Sci. (1975) 53 (1):27–42.
   PubMedGoogle Scholar
• ••Birth of the notion of T-cell co-stimulation.
   Google Scholar
• TALMAGE DW, WOOLNOUGH JA, HEMMINGSEN H et al: Activation of cytotoxic T cells by non-stimulating tumor cells and spleen cell factor(s). Proc. Natl. Acad. Sci. USA (1977) 74(104610–4614.
   Google Scholar
• LAFFERTY KJ, PROWSE SJ, SIMEONOVIC CJ, WARREN HS:Immunobiology of tissue transplantation: a return to the passenger leukocyte concept. Ann. Rev. Immunol. (1983) 1:143–173.
   PubMed Web of Science ®Google Scholar
• BOWEN KM, PROWSE SJ, LAFFERTY KJ: Reversal diabetesby islet transplantation: vulnerability of the estab-lished allograft. Science (1981) 213(4513):1261–1262.
   PubMedGoogle Scholar
• TALMAGE DW, DART G, RADOVICH J, LAFFERTY KJ: Acti-vation of transplant immunity: effect of donor leuko-cytes on thyroid allograft rejection. Science (1976) 191(4225)385–388.
   PubMedGoogle Scholar
• LAFFERTY KJ, COOLEY MA, WOOLNOUGH J, WALKER KZ:Thyroid allograft immunogenicity is reduced after a period in organ culture. Science (1975) 188(4185):259–261.
   PubMedGoogle Scholar
• LINSLEY PS, LEDBETTER JA: The role of the CD28 recep-tor during T cell responses to antigen. Ann. Rev. Immu-nol (1993) 11:191–212.
   PubMed Web of Science ®Google Scholar
• LIU Y, LINSLEY PS: Co-stimulation of T-cell growth.Curr. Opin. Immunol (1992) 4(3):265–270.
   PubMedGoogle Scholar
• FREEMAN GJ, FREEDMAN AS, SEGIL JM et al: B7, a newmember of the Ig superfamily with unique expression on activated and neoplastic B cells. J. Immunol. (1989) 143(8)2714–2722.
   PubMedGoogle Scholar
• HARA T, FU SM, HANSEN JA: Human T cell activation. II.A new activation pathway used by a major T cell popu-lation via a disulfide-bonded dimer of a 44 kilodalton polypeptide (9.3 antigen). J. Exp. Med. (1985) 161(6):1513–1524.
   PubMed Web of Science ®Google Scholar
• JUNE CH, LEDBETTER JA, GILLESPIE MM et al T-cell pro-liferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expres-sion. Mol Cell. Biol. (1987) 7(12):4472–4481.
   PubMed Web of Science ®Google Scholar
• MORETTA A, PANTALEO G, LOPEZ-BOTET M, MORETTA L: Involvement of T44 molecules in an antigen-independent pathway of T cell activation. Analysis of the correlations to the T cell antigen-receptor com-plex. J. Exp. Med. (1985) 162(3):823–838.
   PubMedGoogle Scholar
• LINSLEY PS, BRADY W, URNES M, et al.: CTLA-4 is a sec-ond receptor for the B cell activation antigen B7. J. Exp. Med. (1991) 174(3):561–569.
   PubMed Web of Science ®Google Scholar
• ••First description of CTLA4Ig.
   Google Scholar
• HATHCOCK KS, LASZLO G, DICKLER HB et al: Identifica-tion of an alternative CTLA-4 ligand co-stimulatory for T cell activation. Science (1993) 262(5135):905–907.
   PubMed Web of Science ®Google Scholar
• •Existence of B7–2 revealed.
   Google Scholar
• RAZI-WOLF Z, FREEMAN GJ, GALVIN F et al: Expression and function of the murine B7 antigen, the major co-stimulatory molecule expressed by peritoneal exudate cells. Proc. Natl. Acad. Sci. USA (1992) 89(9):4210–4214.
   PubMedGoogle Scholar
• CHEN C, NABAVI N: In vitro induction of T cell anergy by blocking B7 and early T cell co-stimulatory mole-cule ETC-1/B7-2. Immunity (1994) 1(2):147–154.
   PubMedGoogle Scholar
• BORRIELLO F, SETHNA MP, BOYD SD, et al B7-1 and B7-2 have overlapping, critical roles in immunoglobu-lin class switching and germinal center formation. Im-munity (1997) 6(3):303–313.
   Google Scholar
• CHEN L, ASHE S, BRADY WA, et al: Co-stimulation of an-titumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell (1992) 71(7):1093–1102.
   PubMed Web of Science ®Google Scholar
• ••First demonstration of B7-enhanced tumourimmunogenicity.
   Google Scholar
• BASKAR S, OSTRAND-ROSENBERG S, NABAVI N et al: Constitutive expression of B7 restores immunogenic-ity of tumor cells expressing truncated major histo-compatibility complex class II molecules. Proc. Natl. Acad. Sci. USA (1993) 90(12):5687–5690.
   PubMed Web of Science ®Google Scholar
• TOWNSEND SE, ALLISON JP: Tumor rejection after di-rect co-stimulation of CD8+ T cells by B7-transfected melanoma cells. Science (1993) 259:368–370.
   PubMed Web of Science ®Google Scholar
• RAMARATHINAM L, CASTLE M, WU Y, LIU Y: T cell co-stimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the in-duction, recruitment, and effector function of antitu-mor T cells. J. Exp. Med. (1994) 179(4):1205–1214.
   PubMedGoogle Scholar
• ••First demonstration of a role for B7 at effector phase.
   Google Scholar
• RAMARATHINAM L, SARMA S, MARIC M et al.: Multiple lineages of tumors express a common tumor antigen, PIA, but they are not cross-protected. J. Immunol (1995) 155(10:5323–5329.
   PubMedGoogle Scholar
• JENKINS MK, CHEN CA, JUNG G et al.: Inhibition of antigen-specific proliferation of Type 1 murine T cell clones after stimulation with immobilized anti-CD3 monoclonal antibody. J. Immunol (1990) 144(1):16–22.
   PubMed Web of Science ®Google Scholar
• LIU Y, JANEWAY CAJ: Cells that present both specific ligand and the co-stimulatory activity are the most effi-cient inducer of clonal expansion of normal CD4 T cells. Proc. Natl. Acad. Sci. USA (1992) 89:3845–3849.
   PubMedGoogle Scholar
• •Requirement for co-delivery of antigen and co-stimulator.
   Google Scholar
• LENSCHOW DJ, ZENG Y, THISTLETHWAITE JR et al: Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA41g. Science (1 9 9 2) 257(5071)789–792.
   PubMedGoogle Scholar
• ••Induction of tolerance in vivo by B7 blockade.
   Google Scholar
• FREEMAN GJ, GRAY GS, GIMMI CD et al.: Structure, ex-pression, and T cell co-stimulatory activity of the murine homologue of the human B lymphocyte activa-tion antigen B7. J. Exp. Med (1991) 174(3):625–631.
   PubMedGoogle Scholar
• FREEMAN GJ, GRIBBEN JG, BOUSSIOTIS VA et al.: Clon-ing of B7-2: a CTLA-4 counter-receptor that co-stimulates human T cell proliferation. Science (1993) 262(5135):909–911.
   PubMed Web of Science ®Google Scholar
• ••First cloning of B7–2 molecule.
   Google Scholar
• ARUFFO A, SEED B: Molecular cloning of a CD28 cDNAby a high-efficiency COS cell expression system. Proc. Natl. Acad. Sci. USA (1987) 84 (23):8573–8577.
   PubMedGoogle Scholar
• BRUNET JF, DENIZOT F, LUCIANI MF et al.: A new mem-ber of the immunoglobulin superfamily-CTLA-4. Na-ture (1987) 328(6127):267–270.
   PubMed Web of Science ®Google Scholar
• GROSS JA, ST. JOHN T, ALLISON JP: The murine homo-logue of the T lymphocyte antigen CD28. Molecular cloning and cell surface expression. J. Immunol. (1990) 144 (8):3201–3210.
   PubMed Web of Science ®Google Scholar
• PEACH RJ, BAJORATH J, BRADY W et al.: Complementar-ity determining region 1 (CDR1)-and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1. J. Exp. Med. (1994) 180(6):2049–2058.
   PubMed Web of Science ®Google Scholar
• METZLER WJ, BAJORATH J, FENDERSON W et al: Solution structure of human CTLA-4 and delineation of a CD80/CD86 binding site conserved in CD28 [letter]. Nat. Struct. Biol. (1997) 4(7):527–531.
   PubMedGoogle Scholar
• BORRIELLO F, FREEMAN GJ, EDELHOFF S et al.: Charac-terization of the murine B7-1 genomic locus reveals an additional exon encoding an alternative cytoplasmic domain and a chromosomal location of chromosome 16, band B5. J. Immunol. (1994) 153 (10 :5038–5048.
   PubMedGoogle Scholar
• GUO Y, WU Y, ZHAO M et al.: Mutational analysis and an alternatively spliced product of B7 defines its CD28/CTLA4-binding site on immunoglobulin C-like domain. J. Exp. Med. (1995) 181(4):1345–1355.
   PubMedGoogle Scholar
• INOBE M, LINSLEY PS, LEDBETTER JA et al.: Identifica-tion of an alternatively spliced form of the murine homologue of B7. Biochem. Biophys. Res. Commun. (1994) 200(0:443–449.
   PubMedGoogle Scholar
• PEACH RJ, BAJORATH J, NAEMURA J et al: Both extracel-lular immunoglobin-like domains of CD80 contain residues critical for binding T cell surface receptors CTLA-4 and CD28. J. Biol. Chem. (1995) 270(36):21181–21187.
   PubMedGoogle Scholar
• GUO Y, WU Y, KONG X, LIU Y: Identification of con-served amino acids in murine B7-1IgV domain critical for CTLA4/CD28:B7 interaction by site-directed muta-genesis: a novel structural model of the binding site. Mol Immunol. (1998) 35(4):215–225.
   PubMedGoogle Scholar
• SYMINGTON FW, BRADY W, LINSLEY PS: Expression and function of B7 on human epidermal Langerhans cells. J. Immunol. (1993) 150(4):1286–1295.
   PubMedGoogle Scholar
• VAN DER MERWE PA, BODIAN DL, DAENKE S et al.: CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics. J. Exp. Med. (1997) 185(3)393–403.
   PubMedGoogle Scholar
• DOTY RT, CLARK EA: Two regions in the CD80 cytoplas-mic tail regulate CD80 redistribution and T cell co-stimulation. J. Immunol. (1998) 161(6):2700–2707.
   PubMedGoogle Scholar
• HARDING FA, MCARTHUR JG, GROSS JA et al CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature (1992) 356(6370)607–609.
   PubMedGoogle Scholar
• SHAHINIAN A, PFEFFER K, LEE KP et al.: Differential Tcell co-stimulatory requirements in CD28-deficient mice. Science (1993) 261(5120:609–612.
   PubMedGoogle Scholar
• WU Y, GUO Y, HUANG A et al: CTLA-4-B7 interaction issufficient to co-stimulate T cell clonal expansion. J. Exp. Merl. (1997) 185(7):1327–1335.
   PubMedGoogle Scholar
• •First demonstration of a positive effect of B7-CTLA4 interaction.
   Google Scholar
• LIU Y: Is CTLA-4 a negative regulator for T-cell activa-tion? Immunol. Today (1997) 18(12):569–572.
   Google Scholar
• THOMPSON CB, ALLISON JP: The emerging role of CTLA-4 as an immune attenuator. Immunity (1997) 7(4)445–450.
   PubMedGoogle Scholar
• LINSLEY PS, GREENE JL, TAN P et al: Co-expression and functional co-operation of CTLA-4 and CD28 on acti-vated T lymphocytes. J. Exp. Med. (1992) 176(6):1595–1604.
   PubMed Web of Science ®Google Scholar
• WALUNAS TL, LENSCHOW DJ, BAKKER CY et al.: CTLA-4 can function as a negative regulator of T cell activation. Immunity (1994) 1(5):405–413.
   PubMed Web of Science ®Google Scholar
• •First to propose the novel hypothesis that CTLA4 is a nega-tive regulator.
   Google Scholar
• LINSLEY PS, BRADSHAW J, GREENE J et al.: Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity (1996) 4(6)535–543.
   PubMedGoogle Scholar
• CHUANG E, ALEGRE ML, DUCKETT CS et al.: Interaction of CTLA-4 with the clathrin-associated protein AP50 re-sults in ligand-independent endocytosis that limits cell surface expression. J. Immunol. (1997) 159(1):144–151.
   PubMed Web of Science ®Google Scholar
• ZHANG Y, ALLISON JP: Interaction of CTLA-4 with AP50, a clathrin-coated pit adaptor protein. Proc. Natl. Acad. Sci. USA (1997) 94(17):9273–9278.
   PubMedGoogle Scholar
• SHIRATORI T, MIYATAKE S, OHNO H et al.: Tyrosine phosphorylation controls internalization of CTLA-4 by regulating its interaction with clathrin-associated adaptor complex AP-2. Immunity (1997) 6(5):583–589.
   PubMedGoogle Scholar
• KRUMMEL MF, ALLISON JP: CD28 and CTLA-4 have op-posing effects on the response of T cells to stimulation. J. Exp. Merl. (1995) 182(2):459–465.
   PubMed Web of Science ®Google Scholar
• WATERHOUSE P, PENNINGER JM, TIMMS E et al.: Lym-phoproliferative disorders with early lethality in mice deficient in Ctla-4. Science (1995) 270(5238):985–988.
   PubMed Web of Science ®Google Scholar
• TIVOL EA, BORRIELLO F, SCHWEITZER AN et al.: Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity (1995) 3 (5):541–547.
   PubMed Web of Science ®Google Scholar
• ••Surprising phenotype reveals a significant role of CTLA4 incontrolling autoimmunity.
   Google Scholar
• ZHENG P, WU Y, GUO Y et al.: B7-CTLA4 interaction en-hances both production of antitumor cytotoxic T lym-phocytes and resistance to tumor challenge. Proc. NatL Acad. Sci. USA (1998) 95 (11) :6284–6289.
   PubMedGoogle Scholar
• CILIO CM, DAWS MR, MALASHICHEVA A et al.: Cytotoxic T lymphocyte antigen 4 is induced in the thymus upon in vivo activation and its blockade prevents anti-CD3-mediated depletion of thymocytes. J. Exp. Med. (1998) 188(7) :1239–1246.
   PubMedGoogle Scholar
• WU Y, XU J, SHINDE S et al.: Rapid induction of a novel co-stimulatory activity on B cells by CD40 ligand. Curr. Biol. (1995) 5(10:1303–1311.
   PubMedGoogle Scholar
• SCHWEITZER AN, SHARPE AH: Studies using antigen-presenting cells lacking expression of both B7-1 (CD80) and B7-2 (CD86) show distinct requirements for B7 molecules during priming versus restimulation of Th2 but not Thl cytokine production. J. Immunol (1998) 161(6):2762–2771.
   PubMed Web of Science ®Google Scholar
• KUCHROO VK, DAS MP, BROWN JA et al: B7-1 and B7-2 co-stimulatory molecules activate differentially the Thl /Th2 developmental pathways: application to autoimmune disease therapy. Cell (1995) 80(5)707–718.
   PubMedGoogle Scholar
• HARRIS N, PEACH R, NAEMURA J et al.: CD80 co-stimulation is essential for the induction of airway eosinophilia. J. Exp. Med (1997) 185(0:177–182.
   PubMedGoogle Scholar
• LANIER LL, O'FALLON S, SOMOZA C et al: CD80 (B7) and CD86 (B70) provide similar co-stimulatory signals for T cell proliferation, cytokine production, and genera-tion of CTL. j Immunol. (1995) 154(0:97–105.
   Google Scholar
• LINSLEY PS, GREENE JL, BRADY W et al.: Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors [pub-lished erratum appears in Immunity 1995 Feb;2 (2):fol-lowing 203]. Immunity (1994) 1(9):793–801.
   PubMed Web of Science ®Google Scholar
• MOSMANN TR, COFFMAN RL: TH1 and TH2 cells: differ-ent patterns of lymphokine secretion lead to different functional properties. Ann. Rev. Immunol (1989) 7:145–173.
   PubMed Web of Science ®Google Scholar
• CASTANO L, EISENBARTH GS: Type-I diabetes: a chronic autoimmune disease of human, mouse, and rat. Ann. Rev. Immunol (1990) 8:647–679.
   PubMed Web of Science ®Google Scholar
• WINDHAGEN A, ANDERSON DE, CARRIZOSA A et al: Cy-tokine secretion of myelin basic protein reactive T cells in patients with multiple sclerosis. J. Neuroimmu-nol. (1998) 91(1-2):1–9.
   PubMedGoogle Scholar
• WINDHAGEN A, NICHOLSON LB, WEINER HL et al: Role of Thl and Th2 cells in neurologic disorders. Chem. Im-munol (1996) 63:171–186.
   PubMedGoogle Scholar
• SHIMODA K, VAN DEURSEN J, SANGSTER MY et al: Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature (1996) 380(6575)630–633.
   PubMedGoogle Scholar
• BORRIELLO F, OLIVEROS J, FREEMAN GJ et al: Differen-tial expression of alternate mB7-2 transcripts. J. Immu-nol (1995) 155(12):5490–5497.
   PubMedGoogle Scholar
• AZUMA M, YSSEL H, PHILLIPS JH et al.: Functional ex-pression of B7/BB1 on activated T lymphocytes. J. Exp. Med. (1993) 1 77 (3):845–850.
   Google Scholar
• GREENFIELD EA, HOWARD E, PARADIS T et al.: B7.2 ex-pressed by T cells does not induce CD28-mediated co-stimulatory activity but retains CTLA4 binding: impli-cations for induction of antitumor immunity to T cell tumors. J. Immunol. (1997) 158(5):2025–2034.
   PubMedGoogle Scholar
• ZINKERNAGEL RM: Immunology taught by viruses. Sci-ence (1996) 2u1(5246):173–178.
   Google Scholar
• ALLISON J, STEPHENS LA, KAY TW et al.: The threshold for autoimmune T cell killing is influenced by B7-1. Eur. j Immunol (1998) 28(3):949–960.
   PubMedGoogle Scholar
• WU TC, HUANG AY, JAFFEE EM et al: A reassessment of the role of B7-1 expression in tumor rejection. J. Exp. Med. (1995) 182(5):1415–1421.
   PubMedGoogle Scholar
• SOLDEVILA G, GEIGER T, FLAVELL RA: Breaking immu-nologic ignorance to an antigenic peptide of simian vi-rus 40 large T antigen. J. Immunol. (1 9 9 5) 155(12)5590–5600.
   PubMedGoogle Scholar
• SARMA S, GUO Y, GUILLOUX Y et al.: Cytotoxic T lym-phocytes to an unmutated tumor antigen Elk normal development but restrained effector function. J. Exp. Med. (1999) In Press.
   PubMedGoogle Scholar
• JENKINS MK, ASHWELL JD, SCHWARTZ RH: Allogeneic non-T spleen cells restore the responsiveness of nor-mal T cell clones stimulated with antigen and chemi-cally modified antigen-presenting cells. J. Immunol (1988) 140(10):3324–3330.
   PubMed Web of Science ®Google Scholar
• BASKAR S, GLIMCHER L, NABAVI N et al.: Major histo-compatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J. Exp. Med. (1995) 181(2):619–629.
   PubMed Web of Science ®Google Scholar
• GALVIN F, FREEMAN GJ, RAZI-WOLF Z et al Murine B7 antigen provides a sufficient co-stimulatory signal for antigen-specific and MHC-restricted T cell activation. J. Immunol (1992) 149(12):3802–3808.
   PubMedGoogle Scholar
• MONKS CR, FREIBERG BA, KUPFER H et al.: Three-dimensional segregation of supramolecular activation clusters in T cells. Nature (1998) 395(6697):82–86.
   PubMed Web of Science ®Google Scholar
• MONKS CR, KUPFER H, TAMIR I, et al.: Selective modula-tion of protein kinase C-theta during T-cell activation. Nature (1997) 385(6610:83–86.
   PubMedGoogle Scholar
• LEE KM, CHUANG E, GRIFFIN M et al.: Molecular basis ofT cell inactivation by CTLA-4. Science (1998) 282 (5397):2263–2266.
   PubMed Web of Science ®Google Scholar
• BOON T, CEROTTINI JC, VAN DEN EYNDE B et al.: Tumorantigens recognized by T lymphocytes. Ann. Rev. Im-munol (1994) 12:337–365.
   PubMed Web of Science ®Google Scholar
• CHEN L: Manipulation of T cell response to tumors bytargeting on co-stimulatory pathway. Leukemia (1997) 11 (Suppl. 3):567–569.
   PubMedGoogle Scholar
• BASKAR S: Gene-modified tumor cells as cellular vac-cine. Cancer Immunol. Immunother. (1996) 43 (3):165–173.
   PubMedGoogle Scholar
• CHEN L, LINSLEY PS, HELLSTROM KE: Co-stimulation ofT cells for tumor immunity. Immunol. Today (1993) 14 (10):483–486.
   PubMedGoogle Scholar
• BASKAR S, OSTRAND-ROSENBERG S, NABAVI N, GLIM-CHER L: Constitutive expression of B7 restores immu-nogenicity of tumor cells expressing truncated MHC class II molecules. Proc. Natl. Acad. ScL USA (1993) 90:7015–7019.
   PubMedGoogle Scholar
• MARTIN-FONTECHA A, CAVALLO F, BELLONE M et al Heterogeneous effects of B7-1 and B7-2 in the induc-tion of both protective and therapeutic anti-tumor im-munity against different mouse tumors. Eur. J. Immunol (1996) 26(8):1851–1859.
   PubMedGoogle Scholar
• CAVALLO F, MARTIN-FONTECHA A, BELLONE M et al: Co-expression of B7-1 and ICAM-1 on tumors is re-quired for rejection and the establishment of a mem-ory response. Eur. j Immunol (1995) 25(5):1154–1162.
   PubMedGoogle Scholar
• PULASKI BA, OSTRAND-ROSENBERG S: Reduction of es-tablished spontaneous mammary carcinoma metasta-ses following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res. (1998) 58(7):1486–1493.
   PubMed Web of Science ®Google Scholar
• KWON ED, HURWITZ AA, FOSTER BA et al.: Manipula-tion of T cell co-stimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc. Natl Acad. ScL USA (1997) 94(15):8099–8103.
   PubMed Web of Science ®Google Scholar
• DUNUSSI-JOANNOPOULOS K, WEINSTEIN HJ, NICKER-SON PW et al.: Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML. Blood (1996) 87(7)2938–2946.
   PubMedGoogle Scholar
• HIRANO N, TAKAHASHI T, AZUMA M et al.: Protective and therapeutic immunity against leukemia induced by irradiated B7-1 (CD80)-transduced leukemic cells. Hum. Gene Ther. (1997) 8(10:1375–1384.
   PubMedGoogle Scholar
• SIVANANDHAM M, SHAW P, BERNIK SF et al: Colon can-cer cell vaccine prepared with replication-deficient vaccinia viruses encoding B7.1 and interleukin-2 in-duce antitumor response in syngeneic mice. Cancer Immunol. Immunother. (1998) 46(5):261–267.
   PubMedGoogle Scholar
• FUJII H, INOBE M, KIMURA F et al: Vaccination of tumor cells transfected with the B7-1 (CD80) gene induces the anti-metastatic effect and tumor immunity in mice. Int. J. Cancer (1996) 66(2):219–224.
   PubMedGoogle Scholar
• NARA N, TOHDA S, NAGATA K et al.: Inhibition of the in vitro growth of blast progenitors from acute myelo-blastic leukemia patients by transforming growth factor-beta (TGF-beta). Leukemia (1989) 3(8):572–577.
   PubMedGoogle Scholar
• YANG G, HELLSTROM KE, MIZUNO MT, CHEN L: In vitro priming of tumor-reactive cytolytic T lymphocytes by combining IL-10 with B7-CD28 co-stimulation. J. Im-munol (1995) 155(8):3897–3903.
   PubMedGoogle Scholar
• GAJEWSKI TF, RENAULD JC, VAN PEL A, BOON T: Co-stimulation with B7-1, IL-6, and IL-12 is sufficient for primary generation of murine antitumor cytolytic T lymphocytes in vitro. J. Immunol. (1995) 154 (1 1) :5637–5648.
   PubMed Web of Science ®Google Scholar
• ZAJAC P, SCHUTZ A, OERTLI D et al.: Enhanced genera-tion of cytotoxic T lymphocytes using recombinant vaccinia virus expressing human tumor-associated an-tigens and B7 co-stimulatory molecules. Cancer Res. (1998) 58(20):4567–4571.
   PubMedGoogle Scholar
• CHAMBERLAIN RS, CARROLL MW, BRONTE V et al.: Co-stimulation enhances the active immunotherapy ef-fect of recombinant anticancer vaccines. Cancer Res. (1996) 56(12):2832–2836.
   PubMed Web of Science ®Google Scholar
• CORR M, TIGHE H, LEE D et al.: Co-stimulation provided by DNA immunization enhances antitumor immunity. Immunol (1997) 159(104999–5004.
   Google Scholar
• PUTZER BM, HITT M, MULLER WJ et al.: Interleukin 12 and B7-1 co-stimulatory molecule expressed by an ad-enovirus vector act synergistically to facilitate tumor regression. Proc. Natl. Acad. Sci. USA (1997) 94(20)10889–10894.
   PubMedGoogle Scholar
• EMTAGE PC, WAN Y, BRAMSON JL et al.: A double recom-binant adenovirus expressing the co-stimulatory molecule B7-1 (murine) and human IL-2 induces com-plete tumor regression in a murine breast adenocarci-noma model. J. Immunol. (1998) 160(5):2531–2538.
   PubMedGoogle Scholar
• CHEN L, MCGOWAN P, ASHE S et al.: Tumor immuno-genicity determines the effect of B7 co-stimulation on T cell-mediated tumor immunity. J. Exp. Med. (1994) 179(2)523–532.
   PubMedGoogle Scholar
• HELLSTROM KE, HELLSTROM I, CHEN L: Can stimulated tumor tumor immunity be therapeutically effica-cious? Immunol Rev. (1995) 145:123–145.
   Google Scholar
• YEH KY, PULASKI BA, WOODS ML et al.: B7-1 enhances natural killer cell-mediated cytotoxicity and inhibits tumor growth of a poorly immunogenic murine carci-noma. Cell Immunol (1995) 165(2):217–224.
   PubMedGoogle Scholar
• GELDHOF AB, RAES G, BAKKUS M et al.: Expression of B7-1 by highly metastatic mouse T lymphomas in-duces optimal natural killer cell-mediated cytotoxic-ity. Cancer Res. (1995) 55(13)2730–2733.
   PubMedGoogle Scholar
• CHEN W, PEACE DJ, ROVIRA DK et al: T-cell immunity to the joining region of p210BCR-ABL protein. Proc. Natl. Acad. ScL USA (1992) 89(4):1468–1472.
   PubMed Web of Science ®Google Scholar
• WU Y, LIU Y: Viral induction of co-stimulatory activity on antigen-presenting cells bypasses the need for CD4+ T-cell help in CD8+ T-cell responses. Curr. Biol. (1994) 4(6)499–505.
   PubMedGoogle Scholar
• SCHOENBERGER SP, TOES RE, VAN DER VOORT El et al.: T-cell help for cytotoxic T lymphocytes is mediated by CD4O-CD4OL interactions. Nature (1998) 393(6684)480–483.
   PubMedGoogle Scholar
• RIDGE JP, DI ROSA F, MATZINGER P: A conditioned den-dritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature (1998) 393(6684):474–478.
   PubMed Web of Science ®Google Scholar
• BENNETT SR, CARBONE FR, KARAMALIS F et al.: Help for cytotoxic-T-cell responses is mediated by CD40 signal-ling. Nature (1998) 393(6684)478–480.
   PubMedGoogle Scholar
• TOWNSEND SE, ALLISON JP: Tumor rejection after di-rect co-stimulation of CD8+ T cells by B7-transfected melanoma cells. Science (1993) 259(5093):368–370.
   PubMed Web of Science ®Google Scholar
• CHONG H, HUTCHINSON G, HART IR, VILE RG: Expres-sion of B7 co-stimulatory molecules by B16 melanoma results in a natural killer cell-dependent local anti-tumour response, but induces T-cell-dependent sys-temic immunity only against B7-expressing tumours. Br. J. Cancer (1998) 78(8):1043–1050.
   PubMedGoogle Scholar
• HARLAN DM, HENGARTNER H, HUANG ML et al.: Mice ex-pressing both B7-1 and viral glycoprotein on pancre-atic beta cells along with glycoprotein-specific transgenic T cells develop diabetes due to a breakdown of T-lymphocyte unresponsiveness. Proc. Natl. Acad. Sci. USA (1994) 91(8):3137–3141.
   PubMedGoogle Scholar
• LEACH DR, KRUMMEL MF, ALLISON JP: Enhancement of antitumor immunity by CTLA-4 blockade. Science (1996) 271(5256):1734–1736.
   PubMed Web of Science ®Google Scholar
• •Anti-CTLA4 antibody induces tumour rejection.
   Google Scholar
• MOKYR MB, KALINICHENKO T, GORELIK L, BLUESTONE JA: Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice. Cancer Res. (1998) 58(23):5301–5304.
   PubMed Web of Science ®Google Scholar
• LIU Y, JONES B, ARUFFO A et al: Heat-stable antigen is a co-stimulatory molecule for CD4 T cell growth. J. Exp. Med. (1992) 1 75 (2):437–445.
   Google Scholar
• MUELLER DL, JENKINS MK, SCHWARTZ RH: Clonal ex-pansion versus functional clonal inactivation: a co-stimulatory signalling pathway determines the out-come of T cell antigen receptor occupancy. Ann. Rev. Immunol. (1989) 7:445–480.
   PubMed Web of Science ®Google Scholar
• TRAN HM, NICKERSON PW, RESTIFO AC et al.: Distinct mechanisms for the induction and maintenance of al-lograft tolerance with CTLA4-Fc treatment. J. Immunol. (1997) 159 (5):2232–2239.
   PubMedGoogle Scholar
• TURKA LA, LINSLEY PS, UN H et al.: T-cell activation by the CD28 ligand B7 is required for cardiac allograft re-jection in vivo. Proc. Nad Acad. Sci. USA (1992) 89(22):11102–11105.
   PubMed Web of Science ®Google Scholar
• LINSLEY PS, WALLACE PM, JOHNSON J et al.: Immuno-suppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science (1992) 257(5071)792–795.
   Google Scholar
• IBRAHIM S, JAKOBS F, KITTUR D et al: CTLA4Ig inhibits alloantibody responses to repeated blood transfu-sions. Blood (1996) 88 (12) 4594–4600.
   PubMedGoogle Scholar
• TAN P, ANASETTI C, HANSEN JA et al.: Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J. Exp. Med. (1993) 177(1):165–173.
   PubMed Web of Science ®Google Scholar
• WOODWARD JE, QIN L, CHAVIN KD et al.: Blockade of multiple co-stimulatory receptors induces hypore-sponsiveness: inhibition of CD2 plus CD28 pathways. Transplantation (1996) 62(7):1011–1018.
   PubMed Web of Science ®Google Scholar
• SUN H, SUBBOTIN V, CHEN C et al.: Prevention of chronic rejection in mouse aortic allografts by com-bined treatment with CTLA4-Ig and anti-CD40 ligand monoclonal antibody. Transplantation (19 9 7) 64(12)1838–1843.
   PubMedGoogle Scholar
• UN H, BOLLING SF, LINSLEY PS et al.: Long-term accep-tance of major histocompatibility complex mis-matched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J. Exp. Med. (1993) 178(5):1801–1806.
   PubMedGoogle Scholar
• SAYEGH MH, AKALIN E, HANCOCK WW et al: CD28-B7 blockade after alloantigenic challenge in vivo inhibits Thl cytokines but spares Th2. J. Exp. Med. (1995) 181(5)1869–1874.
   Google Scholar
• LANE P, BURDET C, HUBELE S et al B cell function in mice transgenic for mCTLA4-H gamma 1: lack of ger-minal centers correlated with poor affinity maturation and class switching despite normal priming of CD4+ T cells. J. Exp. Med. (1994) 179(3):819–830.
   PubMedGoogle Scholar
• KRINZMAN SJ, DE SANCTIS GT, CERNADAS M et al: Inhi-bition of T cell co-stimulation abrogates airway hyper-responsiveness in a murine model. J. Clin. Invest. (1996) 98(12):2693–2699.
   PubMed Web of Science ®Google Scholar
• KEANE-MYERS A, GAUSE WC, LINSLEY PS et al.: B7-CD28/CTLA-4 co-stimulatory pathways are required for the development of T helper cell 2-mediated aller-gic airway responses to inhaled antigens. J. Immunol (1997) 158(5)2042–2049.
   PubMedGoogle Scholar
• TSUYUKI S, TSUYUKI J, EINSLE K et al.: Co-stimulation through B7-2 (CD86) is required for the induction of a lung mucosal T helper cell 2 ('1H2) immune response and altered airway responsiveness. J. Exp. Med. (1997) 185 (9) :1671–1679.
   PubMedGoogle Scholar
• VAN OOSTERHOUT AJ, HOFSTRA CL, SHIELDS R et al.: Murine CTLA4-IgG treatment inhibits airway eosino-philia and hyperresponsiveness and attenuates IgE upregulation in a murine model of allergic asthma. Am. J. Respir. Cell Mol. Biol. (1997) 1 7 (3):386–392.
   Google Scholar
• KEANE-MYERS AM, GAUSE WC, FINKELMAN FD et al: De-velopment of murine allergic asthma is dependent upon B7-2 co-stimulation. J. Immunol. (1998) 160(2) :1036–1043.
   PubMedGoogle Scholar
• MARK DA, DONOVAN CE, DE SANCTIS GT et al.: Both CD80 and CD86 co-stimulatory molecules regulate al-lergic pulmonary inflammation. Int. Immunol (1998) 10(10:1647–1655.
   PubMedGoogle Scholar
• LENSCHOW DJ, HEROLD KC, RHEE L et al.: CD28/B7 regulation of Thl and Th2 subsets in the development of autoimmune diabetes [published erratum appears in Immunity (1997) 6(2):215]. Immunity (1996) 5 (3):285–293.
   PubMed Web of Science ®Google Scholar
• LINSLEY PS: The CD28/CTLA-4:B7 receptor system in experimental autoimmune encephalomyelitis [edito-rial; comment]. J. Clin. Invest. (1995) 95(6):2429–2430.
   PubMedGoogle Scholar
• CROSS AH, GIRARD TJ, GIACOLETTO KS et al: Long-term inhibition of murine experimental autoimmune en-cephalomyelitis using CTLA-4-Fc supports a key role for CD28 co-stimulation. J. Clin. Invest. (1995) 95(6)2783–2789.
   PubMedGoogle Scholar
• ARIMA T, REHMAN A, HICKEY WF, FLYE MW: Inhibition by CTLA4Ig of experimental allergic encephalomyeli-tis. J. Immunol. (1996) 156(12):4916–4924.
   PubMed Web of Science ®Google Scholar
• PERRIN PJ, SCOTT D, QUIGLEY L et al.: Role of B7:CD28/CTLA-4 in the induction of chronic relapsing experimental allergic encephalomyelitis. J. Immunol (1995) 154 (3) :1481–1490.
   PubMedGoogle Scholar
• KARANDIKAR NJ, VANDERLUGT CL, BLUESTONE JA, MILLER SD: Targeting the B7/CD28:CTLA-4 co-stimulatory system in CNS autoimmune disease". Neu-roimmunol (1998) 89(1-2):10–18.
   PubMedGoogle Scholar
• GRIGGS ND, AGERSBORG SS, NOELLE RJ et al.: The rela-tive contribution of the CD28 and gp39 co-stimulatory pathways in the clonal expansion and pathogenic ac-quisition of self-reactive T cells. J. Exp. Med. (1996) 183 (3):801–810.
   PubMedGoogle Scholar
• •CTLA4Ig blocks pathogenic aquisition of self-reactive T-cells, but not clonal expansion of antigen-specific T-cells.
   Google Scholar